Learning Objectives 7/28/2017. Hidradenitis Suppurativa: update on associated conditions, co-morbidities, and medical treatment
|
|
- Silvester Parker
- 5 years ago
- Views:
Transcription
1 Hidradenitis Suppurativa: update on associated conditions, co-morbidities, and medical treatment DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Amit Garg, MD S013: Advice from Experts, Medical Dermatology Amit Garg, MD Professor and Founding Chair Department of Dermatology Hofstra Northwell School of Medicine Northwell Health DISCLOSURES AbbVie: Investigator Grant (grant support) AbbVie: Advisor (honorarium) Merck: Investigator (grant support) Pfizer: Advisor (honorarium) Janssen: Advisor (honorarium) Learning Objectives Co-morbidities HS lesions Nodules Abscess Tunnels Scarring Pathogenic factors for HS Hormones Microbiome Tobacco Obesity Stress Genetics Disease associations Describe new observational data on Associated Conditions and Co-Morbidities in HS Discuss updates on the medical management for HS Psychological Depression Anxiety Substance abuse Suicidality Sexual dysfunction CV Risk Tobacco Obesity Diabetes Dyslipidemia Atherosclerosis MACE Inflammatory Spondyloarthropathy SAPHO Pyoderma gangrenosum Crohn s disease Ulcerative colitis Endocrine PCOS Chromosomal Trisomy 21 Adapted from Hoffman et al. Sem Cut Med Surg. 2017;36:48 Peer Reviewed Publications in HS & Psoriasis Using Big Data to Fill Observational Gaps in HS IBM Watson Health Research Platform 50 million unique lives, representative of US population demographics Robust: combines claims and clinical data Power: able to study uncommon diseases and rare events within these diseases Validated cohort of >40,000 patients with HS in the Unites States Keyword search (title or abstract) 1
2 Disease Burden in the United States Burden of Disease in the US Prevalence Incidence Delay in diagnosis Receipt of Treatment Utilization of the Dermatology Visit Prevalence estimates vary significantly across the world ( % to 4.1%) Differing geogrphic samples Selected and/or small cohorts Differing acquisition methods Claims analyses Chart reviews Patient administered questionnaires The true overall prevalence of HS is unknown HS Crude Prev. / 100,000 (95% CI) Stand. Prev / 100,000 (95% CI) Stand Prev (%) Overall 104 ( ) 98 (97-99) 0.10 Female Male 141 ( ) 60 (59-61) 137 ( ) 58 (57-59) (14-15) 155 ( ) 182 ( ) 156 ( ) 122 ( ) 50 (49-51) 15 (14-16) 150 ( ) 172 ( ) 150 ( ) 119 ( ) 49 (48-51) Caucasian Af Am Biracial Other 98 (97-99) 331 ( ) 227 ( ) 38 (37-39) 95 (94-96) 296 ( ) 218 ( ) 36 (35-37) Garg et al. JAMA Dermatol May 10. doi: Garg et al. JAMA Dermatol May 10. doi: HS Stand. Incid. / 100,000 (Ave Annual, ) Stand. Incid. / 100,000 (One Year, ) Overall 8.6 ( ) 11.4 ( ) Female Male ( ) 5.1 ( ) 1.5 ( ) 14.1 ( ) 15.5 ( ) 12.8 ( ) 10.0 ( ) 3.6 ( ) 16.1 ( ) 6.8 ( ) 4.9 ( ) 22.0 ( ) 19.1 ( ) 14.2 ( ) 10.5 ( ) 2.8 ( ) Caucasian Af Am Biracial Other 8.5 ( ) 25.3 ( ) 19.3 ( ) 3.1 ( ) 11.7 ( ) 30.6 ( ) ( ) Garg et al. J Am Acad Dermatol 2017;77(1): Garg et al. J Am Acad Dermatol 2017;77(1):
3 Disease Burden: delays in diagnosis Disease Burden: closing the gaps Global cohort of 517 HS patients Mean time between onset of sxs and 1 st visit with any physician 2.3 years Time between onset of sxs to HS diagnosis 7.2 years Misdiagnoses, inappropriate treatments, and fragmented care disease progression and related morbidity Br J Dermatol 2015;173(6):1546 HS patients have higher disease specific costs for acute care facilities than Psoriasis patients. ED visits HS patients 7.41% vs 2.6% for Pso patients) vs 4.2% for severe Pso patients Hospitalizations HS patients 5.1% vs 1.6% for Psoriasis patients vs 2.5% for severe Pso patients J Amer Acad Dermatol. 2015;73(4):609 Disease Burden: closing the gaps Dermatologists are uniquely positioned to close quality and cost of care gaps for patient with HS Garg et al. JAMA Dermatol.2016;152(5):553 Garg et al. JAMA Dermatol.2016;152(5):553 3
4 Low Utilization of the Dermatology Ambulatory Encounter Among HS Patients Associated Diseases Unpublished data Alzheimer s disease Trisomy 21 Inflammatory Bowel Disease Acne PCOS Pyoderma gangrenosum Spondyloarthropathy Thyroid disease Lymphomas Sleep Apnea Garg et al. unpublished data Gamma Secretase One third of HS patients report a positive Fam Hx Gamma-secretase LOF mutation in a subset of familial HS Multiscaffold protein complex responsible for intra-membrane protein cleavage of many substrates. Nicastrin subunit most commonly mutated Science 2010;330:1065 Candidate substrate: Notch and PI3K/AKT signaling, which regulate KC proliferation and differentiation J Invest Dermatol. 2013;133(3):601 Lancet Neurol. 2010;9(2):215 Dev Cell. 2004;7(5):731 Br J Dermatol. 2013;168(4):876 Science. 2010;19;330(6007):1065 Br J Dermatol.2016;174(3):522 Br J Dermatol 2013;168:871 Gamma Secretase γ-secretase knockouts (mouse) HS-like epidermal and follicular histologic abnormalities Infundibular plugging, cyst formation, and disappearance of sebaceous glands However, no inflammation, abscess,fistulae, or scarring Notch knockouts (mouse) similar to gamma-secretase knockouts, but without infundibular plugging Mice do not have apocrine glands Not all HS patients have γ-secretase mutation There may be substrates other than Notch Br J Dermatol 2013;168:871 Dermatology. 2012;225(1):9 Dev Cell. 2004;7(5):731 4
5 HS and Incident Alzheimer s Disease In the brain, γ-secretase cleaves amyloid precursor protein development of β-amyloid plaques Trisomy 21 and HS Absolute risk Crude OR Adjusted OR Azh Dis 0.2% (65/27,755) 0.34 (95% CI ) 1.23 (95% CI ) Garg et al. J Am Acad Dermatol 2017;77(1):176 Br J Dermatol 2014;170(6):1375 Trisomy 21 and Incident HS Trisomy 21 and Incident HS HS Prevalence T21 Not T21 P Value 2.1% (256/11,936) 0.3% (46,860/16,813,290) <0.001 HS Odds Crude OR 7.84 (95% CI ) Adjusted OR* 5.24 (95% CI ) *Adjusted for age, gender, obesity Garg et al. Br J Dermatol Jun 29. doi: /bjd Trisomy 21 and Incident HS HS & Inflammatory Bowel Disease Cross sectional study in 1,076 HS patients Europe IBD Crohn s UC Prevalence 3.3% (95% CI ) 2.5% (95% CI ) 0.8% (95% CI ) Prevalence of IBD in HS was 4-8 times higher than general European population No difference in phenotype between HS and HS-IBD Garg et al. Br J Dermatol Jun 29. doi: /bjd J Am Acad Dermatol 2017;76:49 5
6 HS & Inflammatory Bowel Disease Cross sectional study in 7,732 HS patients Danish national registry Crohn s UC Prev in HS 0.8% 1.3% Prev in Popl 0.3% 0.7% Odds Ratio Hazard Ratio 2.04 ( ) 2.19 ( ) 1.75 ( ) 1.63 ( ) Cardiovascular Co-morbidity Tobacco smoking Obesity Dylipidemia Diabetes / MetS Major Adverse Cardiac Event J Am Acad Dermatol 2017;76:49 Tobacco/Nicotine and HS Nicotine receptors strongly expressed on follicular epithelium. Up-regulation of nicotinic ACh receptors in HS infundibula Modulates PMN chemotaxis, cytokine production, and macrophage function Down regulation of antimicrobial peptides (beta-defensin) Polyaromatic hydrocarbons and dioxins in cigarette smoke bind to immunomodulatory aryl hydrocarbon receptors Infundibular hyperkeratosis / hyperplasia Tobacco Smoking and HS Frequencies of tobacco smokers within HS cohorts ranges from approximately 30% to as high as 98%. Most analyses based on small sample sizes with little heterogeneity limited generalizability Surgeon 2005;3:23 Exp Dermatol 2006;15:480 Life Sci 2007;80:2214 Int J Dermatol 2005;44:535 Dermatol Clin 2016; 34:51 Exp Dermatol 2012; 21:735 Tobacco Smoking & HS Tobacco Smoking & HS Severity Study König et al Dermatology 1999 Country Cohort size Match / Control Race / Ethn OR Germany 63 Age, Sex Study Sartorius et al BJD 2009 Country Sweden Denmark Cohort size 115 Severity Measure Modified HS Score (HSS) Score Smokers 41 Former Smokers 27 Non Smokers 22 Revuz et al JAAD 2008 Schmitt et al An Bras Dermatol 2012 Schrader et al JAAD 2014 France 302 Age, Sex Brazil 15 Age, Sex Netherland 846 Age, Sex Schrader et al JAAD 2014 Canoui-Poitrine et al JAAD 2009 Vazquez et al JID 2013 Matusiak et al JAAD 2009 Netherlands 846 Hurley No association (adjusted analysis) France 302 Sartorius No association US (Olmstead) 268 Hurley No association (adjusted analysis) Poland 54 Hurley No association 6
7 Tobacco Smoking & HS Unpublished data HS and MACE Retrospective analysis Danish national registry 5964 HS patients and matched controls MACE: MI, Stroke, CV-associated death All-cause mortality Garg et al. Unpublished data JAMA Dermatol. 2016;152(4):429 HS and MACE HS and MACE JAMA Dermatol. 2016;152(4):429 JAMA Dermatol. 2016;152(4):429 HS and MACE Psychiatric Co-morbidity Depression Anxiety Substance Abuse Sexual health Suicidality JAMA Dermatol. 2016;152(4):429 7
8 HS and Substance Abuse Medical Management Unpublished data Topical /Oral Abx IL / Systemic Steroids Oral Retinoids Anti-Androgens Oral-Hypoglucemics Zinc TNFa inhibition IL 12/23 inhibition IL 17 inhibition Garg et al. Unpublished data Clinical Trials in HS Medical Therapies: active, not yet recruiting, recruiting, enrolling Drug Molecule Efficacy studies Adalimumab mab TNFa 2 Apremilast PDE4 inhib 2 IFX-1 Intralesional Triamcinolone Complement inhibitor Glucocorticoid 1 Secukinumab mab IL 17a 1 1 Two Phase III trials (PIONEER I and PIONEER II): safety and efficacy of ADA vs Placebo compare continuation of a weekly dose vs a dose reduction assess maintenance of response after discontinuation Primary endpoint (HiSCR) 50% reduction from baseline in total abscess and inflammatory nodule count, with no increase in the abscess or draining-fistula count ClinicalTrials.gov, July 2017 N= 633 total across 101 sites in 14 countries Mod to Severe HS, inadequate response to oral Antibiotics Randomized Double Blind Placebo Controlled Period 1 (12wks) Period 2 (24 wks) 8
9 IL 12/23 in Lesional Dermis J Am Acad Dermatol. 2011;65(4):790 IL 12/23 Inhibition: Ustekinumab IL 17 in Lesional Dermis Open-label study, n=17 Ustekinumab 45 or 90 mg (Pso dosing) at wks 0, 4, 16 and 28, then monitored for another 12 wks Outcome : msartorius or HiSCR wks 6/17 (35%) marked improvement in mss 3/17 (18%) moderate improvement in mss 8/17 (47%) achieved HiSCR 50 Br J Dermatol 2016;174:839 J Am Acad Dermatol. 2011;65(4):790 9
10 IL 17 Inhibition Challenges to Address Scattered case reports of efficacy Trials are on the way! How well do our existing instruments measure HS? Have we (experts and patients) defined what needs to be measured in HS? And can we agree? What do existing instruments capture well? Not so well? How reliable are HS measurement instruments? Hurley, Modified Sartorius, HS Severity Index, HS-PGA, HiSCR, AISI, HS4 How well do our instruments measure change in disease status? HIdradenitis SuppuraTiva core outcomes set International Collaboration Thank you Amit Garg, MD Professor and Founding Chair Department of Dermatology Hofstra School of Medicine Northwell Health 10
Hidradenitis Suppurativa
1 Hidradenitis Suppurativa Therapeutic Update Francisco A. Kerdel BSc, MBBS Director of Dermatology Inpatient Service Larkin Community Hospital, Miami, Fl Clinical Professor and Vice Chairman of Dermatology
More informationAccepted Manuscript. Overall and Subgroup Prevalence of Acne Vulgaris Among Patients with Hidradenitis Suppurativa
Accepted Manuscript Overall and Subgroup Prevalence of Acne Vulgaris Among Patients with Hidradenitis Suppurativa Sara Wertenteil, BA, Andrew Strunk, MA, Amit Garg, MD PII: S01909622(18)329128 DOI: https://doi.org/10.1016/j.jaad.2018.11.022
More informationJEADV SHORT REPORT. Abstract
DOI: 1.1111/jdv.13216 JEADV SHORT REPORT HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the
More informationEvangelos J. Giamarellos-Bourboulis 1, Maria Argyropoulou 1, Theodora Kanni 1, Isabell Kopka 2, Othmar Zenker 2
EFFICACY AND SAFETY OF IFX-1, AN ANTI-C5A MONOCLONAL ANTIBODY, IN AN OPEN-LABEL, PHASE 2A STUDY IN PATIENTS WITH SEVERE HIDRADENITIS SUPPURATIVA NOT ELIGIBLE FOR ADALIMUMAB Evangelos J. Giamarellos-Bourboulis
More informationIncorporating Biologics Into Your Practice
Incorporating Biologics Into Your Practice Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Disclosure Of Relationships With Industry Amgen AbbVie Celgene
More informationUpdate on systemic therapies and emerging treatments How do I choose a systemic agent?
Update on systemic therapies and emerging treatments How do I choose a systemic agent? Amy S. Paller, M.D. Walter J. Hamlin Professor and Chair of Dermatology Professor of Pediatrics Northwestern University
More informationHidradenitis and other inmune mediated skin diseases. Dr. Antonio Martorell Hospital de Manises, Valencia
Hidradenitis and other inmune mediated skin diseases Dr. Antonio Martorell Hospital de Manises, Valencia Hidradenitis y dermatitis atópica a Pictures courtesy of Antonio Martorell MD Ph.D Topical Resorcinol
More informationDRAFT FOR PUBLIC CONSULTATION. Clinical Commissioning Policy Proposition: Infliximab for the treatment of hidradenitis suppurativa
Clinical Commissioning Policy Proposition: Infliximab for the treatment of hidradenitis suppurativa Information Reader Box (IRB) to be inserted on inside front cover for documents of 6 pages and over,
More informationThe objective of this study was to assess the effect
Adalimumab is Associated with Reduced Skin Pain in Patients with Moderate to Severe Hidradenitis Suppurativa (HS): Results from the First 12 Weeks of PIONEER II Alexandra B Kimball 1, Brett Pinsky 2, Ziqian
More information2.0 Synopsis. Adalimumab M Clinical Study Report R&D/13/1011. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: Name of Active Ingredient: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title of Study: A Phase 3 Multicenter
More informationPersonalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment
Personalized Medicine Selecting the Right First-line Biologic Agent William Tremaine, M.D. Maxine and Jack Zarrow Professor Mayo Clinic Rochester, MN, USA The Right Treatment Pretreatment Genomic Analysis
More informationUse of medical record databases to study psoriasis
Use of medical record databases to study psoriasis Joel M. Gelfand, MD, MSCE Professor of Dermatology and Epidemiology Vice Chair for Clinical Research Medical Director, Clinical Studies Unit Director,
More informationHidradenitis Suppurativa
Disclosures Hidradenitis Suppurativa I have no conflicts of interest Will discuss off-label uses of medications Jennifer Hsiao, MD UCLA Dermatology Background information Clinical features Treatments Lifestyle
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationSystemic diseases. Dra. Raquel Rivera
Systemic diseases Dra. Raquel Rivera Hidradenitis Suppurativa Wednesday, 12th September 2018 International Society Meeting: EHSF - European Hidradenitis Suppurativa Foundation 13:30-17:30 Place: Room 252AB
More informationRosacea Update: Rosacea pathogenesis. Rosacea genetics. Disclosures. Rosacea: Etiology? Th1/Th17 is activated in rosacea skin
Winter Clinical Big Island 20 min Rosacea Update: 2017 Diane M. Thiboutot, M.D. Professor of Dermatology The Pennsylvania State University College of Medicine Hershey, PA Disclosures Investigator or consultant
More informationThe Treatment Toolbox for Severe Pediatric Psoriasis
The Treatment Toolbox for Severe Pediatric Psoriasis Dr. Kim A. Papp, MD, PhD, FRCPC, FAAD K Papp Clinical Research and Probity Medical Research Objectives: Treating severe pediatric psoriasis 1. Challenges
More informationUSTEKINUMAB and BRIAKINUMAB
USTEKINUMAB and BRIAKINUMAB Andrew Blauvelt, M.D. Professor, Dept. of Dermatology and Dept. of Molecular Microbiology & Immunology Oregon Health & Science University Chief, Dermatology Service Veteran
More informationTechnology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta392
Adalimumab for treating moderate to severe ere hidradenitis suppurativa Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta392 NICE 2018. All rights reserved. Subject to Notice
More informationPediatric Psoriasis Comorbidities. Kelly M. Cordoro, M.D. Associate Professor of Dermatology and Pediatrics University of California, San Francisco
Pediatric Psoriasis Comorbidities Kelly M. Cordoro, M.D. Associate Professor of Dermatology and Pediatrics University of California, San Francisco log2 (Expression/hARP) Th1 CXCL10 Disclosures * *** **
More informationPediatric Psoriasis:
Pediatric Psoriasis: What s New, What s True? Kelly M. Cordoro, M.D. Associate Professor of Dermatology and Pediatrics University of California, San Francisco Kelly.cordoro@ucsf.edu Disclosures Consultant
More informationSingle Technology Appraisal (STA) Adalimumab for treating moderate to severe hidradenitis suppurativa
Single Technology Appraisal (STA) Adalimumab for treating moderate to severe Comment 1: the draft remit Response to consultee and commentator comments on the draft remit and draft scope (pre-referral)
More informationMichael P. Heffernan, M.D San Luis Dermatology & Laser Clinic Director, US Probity Medical Research
Michael P. Heffernan, M.D San Luis Dermatology & Laser Clinic Director, US Probity Medical Research mpheffernanmd@gmail.com DISCLOSURES Consultant, Speaker, Investigator: Abbvie, Amgen, Brickell Biotech,
More informationEvaluating Psoriasis: Patient Reported Outcomes and Impact of Disease
Evaluating Psoriasis: Patient Reported Outcomes and Impact of Disease Bruce E. Strober, MD, PhD Professor and Chair Department of Dermatology University of Connecticut Farmington, Connecticut DISCLOSURE
More informationHighlights of DDW 2015: Crohn s disease
Highlights of DDW 2015: Crohn s disease Mark S. Silverberg, MD, PhD, FRCPC Associate Professor of Medicine, University of Toronto Staff Gastroenterologist, Mount Sinai Hospital Senior Investigator, Lunenfeld-Tanenbaum
More informationEtanercept for Treatment of Hidradenitis
Home Search Browse Resources Help What's New About Purpose Etanercept for Treatment of Hidradenitis This study is currently recruiting patients. Sponsors and Collaborators: University of Pennsylvania Amgen
More informationHIDRADENITIS SUPPURATIVA
Print Close Window Note: Large images and tables on this page may necessitate printing in landscape mode. Copyright 2004-2005 The McGraw-Hill Companies. All rights reserved. Fitzpatrick Color Atlas, 5e
More informationHidradenitis Suppurativa. Young-San, Jeon. Department of Surgery Thyroid and breast center, Goo Hospital
Hidradenitis Suppurativa Young-San, Jeon Department of Surgery Thyroid and breast center, Goo Hospital Definition Hidradenitis suppurativa/acne inversa (HS) is a chronic, inflammatory, recurrent, debilitating
More informationBJD British Journal of Dermatology. Summary. What s already known about this topic? What does this study add?
EPIDEMIOLOGY AND HEALTH SERVICES RESEARCH BJD British Journal of Dermatology Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study C.B. Kromann, 1 I.E.
More informationRisk of Pneumocystosis among Patients Receiving Immunosuppressive Therapies: a population based analysis in the United States
Risk of Pneumocystosis among Patients Receiving Immunosuppressive Therapies: a population based analysis in the United States Sergey Rekhtman MD, PharmD, MPH Amit Garg, MD Department of Dermatology Zucker
More informationJ. Gelfand 1, A. Joshi 2, D. Shin 1, A. Dey 2, D. Torigian 1, D. Rader 1, M. Playford 2, M. Ahlman 2, A. Alavi 1, N. Mehta 2.
A Trial to Determine the Effect of Psoriasis Treatment (Adalimumab, Phototherapy, and placebo) on Cardiometabolic Disease: The Vascular Inflammation in Psoriasis (VIP) Trial Abstract 393 J. Gelfand 1,
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationPGA x BSA as a PASI Surrogate
PGA x BSA as a PASI Surrogate Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan Hospital New York, NY, USA DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY
More informationIncidence of Hidradenitis Suppurativa and Associated Factors: A Population-Based Study of Olmsted County, Minnesota
ORIGINAL ARTICLE and Associated Factors: A Population-Based Study of Olmsted County, Minnesota Benjamin G. Vazquez 1,3, Ali Alikhan 1,3, Amy L. Weaver 2, David A. Wetter 1 and Mark D. Davis 1 There are
More informationUniversity of Groningen. Hidradenitis suppurativa Dickinson-Blok, Janine Louise
University of Groningen Hidradenitis suppurativa Dickinson-Blok, Janine Louise IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationBrodalumab for treating moderate to severe plaque psoriasis [ID878]
Brodalumab for treating moderate to severe plaque psoriasis [ID878] Thank you for agreeing to give us your organisation s views on this technology and its possible use in the NHS. You can provide a unique
More informationIBD in teenagers Biological and Transition
IBD in teenagers Biological and Transition Dr Warren Hyer Consultant Paediatric Gastroenterologist St Mark s Hospital Chelsea and Westminster Hospital Conflict of Interest None to declare Fee for presentation
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More informationWhat you need to know about HS HIDRADENITIS SUPPURATIVA. Hidradenitis Suppurativa
What you need to know about HS HIDRADENITIS SUPPURATIVA HS Hidradenitis Suppurativa The Irish Skin Foundation is a national charity with a mission to improve quality of life for people with skin conditions,
More informationChapter 19 Hidradenitis Suppurativa
1 Chapter 19 Hidradenitis Suppurativa Peter Nthumba Hidradenitis suppurativa is a chronic, recurrent, painful inflammatory skin disease, first described in 1833 by a French surgeon. Verneuil, another French
More informationPsoriasis. Jessica Kaffenberger, M.D. Assistant Professor of Dermatology Division of Dermatology The Ohio State University Wexner Medical Center
Psoriasis Jessica Kaffenberger, M.D. Assistant Professor of Dermatology Division of Dermatology The Ohio State University Wexner Medical Center Learning objectives Recognize the different types of psoriasis
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationSTABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators
STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:
More informationNIH Public Access Author Manuscript J Invest Dermatol. Author manuscript; available in PMC 2013 July 01.
NIH Public Access Author Manuscript Published in final edited form as: J Invest Dermatol. 2013 January ; 133(1): 97 103. doi:10.1038/jid.2012.255. Incidence of Hidradenitis Suppurativa and Associated Factors:
More informationIndication Review: Humira (adalimumab) for Hidradenitis Suppurativa
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPopulation-based Clinical Practice Research Datalink study using. algorithm modelling to identify the true burden of hidradenitis.
DR JOHN R INGRAM (Orcid ID : 0000-0002-5257-1142) Article type : Original Article Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis
More informationUniversity of Groningen. Hidradenitis suppurativa Dickinson-Blok, Janine Louise
University of Groningen Hidradenitis suppurativa Dickinson-Blok, Janine Louise IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More information6/17/2018. Comorbidities in Hidradenitis: Fact or Fiction. What is the best estimate of the rate of arthropathy for people with HS?
Comorbidities in Hidradenitis: Fact or Fiction Joslyn S. Kirby, MD, MS, MEd Department of Dermatology Penn State Milton S. Hershey Medical Center, Hershey PA Conflicts & Financial Disclosures for HS: AbbVie:
More informationCathepsin S Inhibitors for the Treatment of Inflammatory Bowel Disease. Therapeutic Area Partnerships Presentation.
Inhibitors for the Treatment of Inflammatory Bowel Disease Therapeutic Area Partnerships Presentation November 29, 2012 Cathepsin Cysteine Proteinases Fibrosis Cathepsin O Cathepsin B Cathepsin C Cathepsin
More informationKey causes of preventable deaths in New Zealand In a population of 10,000 New Zealanders, every year there will be about:
Preventive care - Chronic Disease Management in primary care: a population perspective Rod Jackson University of Auckland New Zealand (22/11/8) Key causes of preventable deaths in New Zealand In a population
More informationHidradenitis suppurativa
Hidradenitis suppurativa Key points Hidradenitis suppurativa is a chronic relapsing inflammatory condition affecting the skin and subcutaneous tissue It manifests as painful deep nodules, abscesses, sinus
More informationReproducibility among dermatologists of outcome measure. instruments used in hidradenitis suppurativa: Protocol for an agreement and reliability study
Reproducibility among dermatologists of outcome measure instruments used in hidradenitis suppurativa: Protocol for an agreement and reliability study Linnea Thorlacius 1,2, Amit Garg 3, Peter Theut Riis
More informationSTELARA (ustekinumab) Clinical Study Report CNTO1275CRD3001
SYNOPSIS Name of Sponsor/Company Janssen Research & Development* Name of Investigational Product STELARA (ustekinumab) * Janssen Research & Development is a global organization that operates through different
More informationEconomic Evaluation of Apremilast in the Treatment of Moderate to Severe Psoriasis in the United States
1142 Economic Evaluation of Apremilast in the Treatment of Moderate to Severe Psoriasis in the United States Tom Tencer, PhD 1 ; Zoe Clancy, PharmD, MS 1 ; Vidya Damera, MS 2 ; Frank Zhang MD, MPH 1 ;
More informationSelection and use of the non-anti- TNF biological therapies: Who? When? How?
Selection and use of the non-anti- TNF biological therapies: Who? When? How? Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz Division of Gastroenterology The Icahn School of Medicine
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationGuselkumab for treating moderate to severe plaque psoriasis [ID1075]
Guselkumab for treating moderate to severe plaque psoriasis [ID1075] Thank you for agreeing to give us your organisation s views on this technology and its possible use in the NHS. You can provide a unique
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationIs Apremilast (Otezla) Effective in Reducing Pruritus in Adults over 18 Years Old with Plaque Psoriasis?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 3-2017 Is Apremilast (Otezla) Effective in
More information75th AAD Annual Meeting
75th AAD Annual Meeting Poster nº 4873 A phase 3 randomized, double-blind, trial comparing the efficacy and safety of the fixed combination calcipotriene 0.005% (Cal) and betamethasone dipropionate 0.064%
More informationSYNOPSIS. Issue Date: 25 Oct 2011
SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:
More informationSpartan Medical Research Journal
Spartan Medical Research Journal Research at Michigan State University College of Osteopathic Medicine Volume 3 Number 2 Fall, 2018 Pages 92-99 Title: A Novel Treatment of Acne Fulminans with Adalimumab:
More informationThe Cosentyx clinical trial programme 1-11
The Cosentyx clinical trial programme 1-11 There are eight pivotal trials (four in psoriasis, two in psoriatic arthritis, two in ankylosing spondylitis) There are two head-to-head trials in psoriasis showing
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Characterization of Disease Burden, Comorbidities and Use of Patients with Psoriasis at Enrollment: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo
More informationSurveillance report Published: 9 January 2017 nice.org.uk
Surveillance report 2017 Caesarean section (2011) NICE guideline CG132 Surveillance report Published: 9 January 2017 nice.org.uk NICE 2017. All rights reserved. Contents Surveillance decision... 3 Reason
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationF061 - Late-breaking Research: Clinical Trials Saturday, February 17 1:00 PM 3:00 PM Ballroom 20A. 1:00 pm - 1:10 pm
1:00 pm - 1:10 pm 6533 - Primary Results from a Phase 2b, Randomized, Placebo-Controlled Trial of Upadacitinib for Patients with Atopic Dermatitis /Emma Guttman, MD, PhD Objective 1: Report primary efficacy
More informationDisclosures. Activity Information. Updates in Psoriasis Therapy. Ustekinumab Guselkumab Tildrakizumab. Secukinumab Ixekizumab Brodalumab
Disclosures Faculty: Teri Greiling, MD, PhD, has disclosed the following conflicts of interest: research funding: Eli Lilly. Updates in Psoriasis Therapy 12 October 2018 St. Charles Medical Center Teri
More informationClinical Policy Title: Intralesional steroid injection for acne
Clinical Policy Title: Intralesional steroid injection for acne Clinical Policy Number: 16.02.07 Effective Date: June 1, 2017 Initial Review Date: April 19, 2017 Most Recent Review Date: May 19, 2017 Next
More informationPsoriasiform Dermatitis in Children: Calling in the Troops
Psoriasiform Dermatitis in Children: Calling in the Troops Markus Boos, MD PhD Attending Physician, Dermatology Seattle Children s Hospital Assistant Professor of Pediatrics, University of Washington School
More informationPrior Authorization Conditions for Approval of Humira (adalimumab) Website Form Submit request via: Fax
Prior Authorization Conditions for Approval of Humira (adalimumab) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Humira (adalimumab) require a prior
More informationDiseases in which appear swelling, redness, pain and heat; aspects of the immune system (Inflammatory and immunologic conditions-imid)
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Prednisolone is generally preferred amongst glucocorticoids for anti-inflammatory and immunosuppressive treatment. There are three
More informationthe high CVD risk smoker
Smoking Cessation: population and patients A comprehensive approach to the smoker the high CVD risk smoker Catriona Jennings Cardiovascular Specialist Research Nurse Imperial College London European Society
More information(minutes for web publishing)
Dermatology Subcommittee of the Pharmacology and Therapeutics Advisory Committee (PTAC) Meeting held on 20 October 2017 (minutes for web publishing) Dermatology Subcommittee minutes are published in accordance
More informationGender Differences in Autoimmune Diseases
//9 Impact of Gender on the Pathogenesis of Crohn s Disease Theresa T. Pizarro Department of Pathology, CWRU Gender Differences in Autoimmune Diseases n Autoimmune diseases affect ~.7-. million people
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More informationInsights from the Kaiser Permanente database
Insights from the Kaiser Permanente database Jashin J. Wu, M.D. Founding Director of Dermatology Research Director, Psoriasis Clinic Department of Dermatology Kaiser Permanente Los Angeles Medical Center
More informationchemotherapeutic agents in
Use of biologics and chemotherapeutic agents in cutaneous emergencies: Focus on lifethreatening forms of psoriasis Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationBiologics in Psoriasis. Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre
Biologics in Psoriasis Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre Disclosures Consultancy services for Celgene, Centocor, Almirall, Amgen, Pfizer, Philips,
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1041-8 Program Prior Authorization/Notification Medication Humira (adalimumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,
More informationChantix Label Update 2018
Chantix Label Update 2018 Chantix (varenicline) Prescribing Information Chantix Prescribing Info URL and Disclaimer Please refer to the full Prescribing Information on important treatment considerations
More informationDevelopments in Psoriasis Management Celgene Corporation 07/14 USII-CELG140030
Developments in Psoriasis Management 2014 Celgene Corporation 07/14 USII-CELG140030 Psoriasis (PsO) Is a Chronic Inflammatory Disease That Can Impact Patients Health-Related Quality of Life PsO is a chronic
More informationBiologic Therapy for Ulcerative Colitis in 2015
5/6/215 Biologic Therapy for Ulcerative Colitis in 215 John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University Bressler B, Marshall JK, et al. Gastroenterology 215;148: 135-58
More informationPharmacotherapy for Tobacco Dependence Treatment
Pharmacotherapy for Tobacco Dependence Treatment Nancy Rigotti, MD Professor of Medicine, Harvard Medical School Director, Tobacco Research and Treatment Center, Massachusetts General Hospital nrigotti@partners.org
More informationHidradenitis suppurativa
PEER REVIEWED FEATURE 2 CPD POINTS Hidradenitis suppurativa Debilitating and challenging to treat VICTORIA HARRIS MB BS, LLB ANDREW LEE MB BS, MMed SHIVAM KAPILA MB BS, BSc(Med), MS ALAN COOPER OAM, BSc,
More informationDISCLOSURES WHAT S NEW AND EXCITING FROM JAAD
WHAT S NEW AND EXCITING FROM JAAD Bruce H. Thiers, MD, Editor, JAAD Professor, Medical University of South Carolina Department of Dermatology and Dermatologic Surgery DISCLOSURES PFIZER VALEANT EFFECT
More informationIdentification of Three Hidradenitis Suppurativa Phenotypes: Latent Class Analysis of a Cross-Sectional Study
ORIGINAL ARTICLE See related commentary on pg 1453 Identification of Three Hidradenitis Suppurativa Phenotypes: Latent Class Analysis of a Cross-Sectional Study Florence Canoui-Poitrine 1,2,6, Aurélie
More informationNovan Provides Update on SB414 Inflammatory Skin Disease Development Program
Novan Provides Update on SB414 Inflammatory Skin Disease Development Program SB414 Nitric Oxide-Releasing Cream Safe and Well-Tolerated in Psoriasis Phase 1b Trial Preclinical Data with SB414 Targeting
More informationEpidemiology of IBD in Pediatric Patients in the US: Data from the ImproveCareNow Registry
Epidemiology of IBD in Pediatric Patients in the US: Data from the ImproveCareNow Registry Michael D. Kappelman, MD Professor of Pediatrics and Epidemiology University of North Carolina, Chapel Hill Richard
More informationAccepted Manuscript. Does eradication of Helicobacter pylori cause inflammatory bowel disease? Johan Burisch, Tine Jess
Accepted Manuscript Does eradication of Helicobacter pylori cause inflammatory bowel disease? Johan Burisch, Tine Jess PII: S1542-3565(19)30153-3 DOI: https://doi.org/10.1016/j.cgh.2019.02.013 Reference:
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Remicade, Renflexis and Inflectra are tumor necrosis factor (TNFα) blockers. Tumor necrosis factor is an endogenous protein that regulates a number of physiologic
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Humira (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationEvolving Challenges in the Evaluation and Treatment of Lower Extremity PAD -- The Peripheral Academic Research Consortium (PARC)
Evolving Challenges in the Evaluation and Treatment of Lower Extremity PAD -- The Peripheral Academic Research Consortium (PARC) W. Schuyler Jones, MD FACC Director, Adult Cardiac Catheterization Laboratory
More informationThe role of current biologic therapies in psoriasis
: An Update on and IL-17 Inhibitors Joanna Dong, BA; Gary Goldenberg, MD PRACTICE POINTS The newest biologics for treatment of moderate to severe plaque psoriasis are and IL-17 inhibitors with unprecedented
More information